Prime Medicine named asLeader among 12 other companies, includingBeam Therapeutics,Editas Medicine, andVerve Therapeutics. You're one click awayfrom the most comprehensive, unmatched analyst expertise in tech, in-depth private company data and a platform that brings it all together. ...
prime editing is inherently resistant to off-target editing or bystander editing, and can proceed with few indel byproducts or other undesired consequences of double-strand DNA breaks1,12,13,14,15,16,17,18,19,20,21.
The FDA approved Revance Therapeutics’ Daxxify in September 2022, a new botulinum toxin agent to freeze facial wrinkles, which, based on the manufacturer’s evidence, can last for up to 6 months. The formula is stabilised with peptides rather than animal protein or human serum, which paved ...
(This article belongs to the Special IssueRNA Therapeutics) Downloadkeyboard_arrow_down Browse Figures Versions Notes Abstract Adenosine Deaminases Acting on RNA (ADARs) are members of a family of RNA editing enzymes that catalyze the conversion of adenosine into inosine in double-stranded RNA (dsRNA...